Advisory Committee Split On Whether FDA Should Draft Nanotech Guidance
This article was originally published in The Tan Sheet
Executive Summary
FDA currently lacks information to draft effective guidance about the development of nanotechnology derived drug applications, according to a majority of FDA's Pharmaceutical Science and Clinical Pharmacology advisory committee
You may also be interested in...
FDA Nanotech Guidance Takes Small Step Forward
FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.
FDA Nanotech Guidance Takes Small Step Forward
FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.
FDA Nanotech Guidance Takes Small Step Forward
FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.